OBJECTIVES: The goal of this study was to examine the prospective association between oxidation-specific biomarkers, primarily oxidized phospholipids (OxPL) on apolipoprotein B-100-containing lipoproteins (OxPL/apoB) and lipoprotein (a) [Lp(a)], and risk of peripheral artery disease (PAD). We examined, as secondary analyses, indirect measures of oxidized lipoproteins, including autoantibodies to malondialdehyde-modified low-density lipoprotein (MDA-LDL) and apolipoprotein B-100 immune complexes (ApoB-IC). BACKGROUND: Biomarkers to predict the development of PAD are lacking. OxPL circulate in plasma, are transported by Lp(a), and deposit in the vascular wall and induce local inflammation. METHODS: The study population included 2 parallel nested case-control studies of 143 men within the Health Professionals Follow-up Study (1994 to 2008) and 144 women within the Nurses' Health Study (1990 to 2010) with incident confirmed cases of clinically significant PAD, matched 1:3 to control subjects. RESULTS: Levels of OxPL/apoB were positively associated with risk of PAD in men and women: pooled relative risk: 1.37, 95% confidence interval: 1.19 to 1.58 for each 1-SD increase after adjusting age, smoking, fasting status, month of blood draw, lipids, body mass index, and other cardiovascular disease risk factors. Lp(a) was similarly associated with risk of PAD (pooled adjusted relative risk: 1.36; 95% confidence interval: 1.18 to 1.57 for each 1-SD increase). Autoantibodies to MDA-LDL and ApoB-IC were not consistently associated with risk of PAD. CONCLUSIONS: OxPL/apoB were positively associated with risk of PAD in men and women. The major lipoprotein carrier of OxPL, Lp(a), was also associated with risk of PAD, reinforcing the key role of OxPL in the pathophysiology of atherosclerosis mediated by Lp(a).
OBJECTIVES: The goal of this study was to examine the prospective association between oxidation-specific biomarkers, primarily oxidized phospholipids (OxPL) on apolipoprotein B-100-containing lipoproteins (OxPL/apoB) and lipoprotein (a) [Lp(a)], and risk of peripheral artery disease (PAD). We examined, as secondary analyses, indirect measures of oxidized lipoproteins, including autoantibodies to malondialdehyde-modified low-density lipoprotein (MDA-LDL) and apolipoprotein B-100 immune complexes (ApoB-IC). BACKGROUND: Biomarkers to predict the development of PAD are lacking. OxPL circulate in plasma, are transported by Lp(a), and deposit in the vascular wall and induce local inflammation. METHODS: The study population included 2 parallel nested case-control studies of 143 men within the Health Professionals Follow-up Study (1994 to 2008) and 144 women within the Nurses' Health Study (1990 to 2010) with incident confirmed cases of clinically significant PAD, matched 1:3 to control subjects. RESULTS: Levels of OxPL/apoB were positively associated with risk of PAD in men and women: pooled relative risk: 1.37, 95% confidence interval: 1.19 to 1.58 for each 1-SD increase after adjusting age, smoking, fasting status, month of blood draw, lipids, body mass index, and other cardiovascular disease risk factors. Lp(a) was similarly associated with risk of PAD (pooled adjusted relative risk: 1.36; 95% confidence interval: 1.18 to 1.57 for each 1-SD increase). Autoantibodies to MDA-LDL and ApoB-IC were not consistently associated with risk of PAD. CONCLUSIONS:OxPL/apoB were positively associated with risk of PAD in men and women. The major lipoprotein carrier of OxPL, Lp(a), was also associated with risk of PAD, reinforcing the key role of OxPL in the pathophysiology of atherosclerosis mediated by Lp(a).
Authors: Sotirios Tsimikas; Claes Bergmark; Reinaldo W Beyer; Raj Patel; Jennifer Pattison; Elizabeth Miller; Joseph Juliano; Joseph L Witztum Journal: J Am Coll Cardiol Date: 2003-02-05 Impact factor: 24.094
Authors: Mary McGrae McDermott; Kiang Liu; Philip Greenland; Jack M Guralnik; Michael H Criqui; Cheeling Chan; William H Pearce; Joseph R Schneider; Luigi Ferrucci; Lillian Celic; Lloyd M Taylor; Ed Vonesh; Gary J Martin; Elizabeth Clark Journal: JAMA Date: 2004-07-28 Impact factor: 56.272
Authors: Sotirios Tsimikas; Herbert K Lau; Kyoo-Rok Han; Brian Shortal; Elizabeth R Miller; Amit Segev; Linda K Curtiss; Joseph L Witztum; Bradley H Strauss Journal: Circulation Date: 2004-06-07 Impact factor: 29.690
Authors: Deepti Gurdasani; Barbara Sjouke; Sotirios Tsimikas; G Kees Hovingh; Robert N Luben; Nicholas W J Wainwright; Cristina Pomilla; Nicholas J Wareham; Kay-Tee Khaw; S Matthijs Boekholdt; Manjinder S Sandhu Journal: Arterioscler Thromb Vasc Biol Date: 2012-10-11 Impact factor: 8.311
Authors: Anand Prasad; Paul Clopton; Colby Ayers; Amit Khera; James A de Lemos; Joseph L Witztum; Sotirios Tsimikas Journal: Arterioscler Thromb Vasc Biol Date: 2017-05-04 Impact factor: 8.311
Authors: Andrew P DeFilippis; Ilya Chernyavskiy; Alok R Amraotkar; Patrick J Trainor; Shalin Kothari; Imtiaz Ismail; Charles W Hargis; Frederick K Korley; Gregor Leibundgut; Sotirios Tsimikas; Shesh N Rai; Aruni Bhatnagar Journal: J Thromb Thrombolysis Date: 2016-07 Impact factor: 2.300
Authors: Sotirios Tsimikas; Gordon W Duff; Peter B Berger; John Rogus; Kenneth Huttner; Paul Clopton; Emmanuel Brilakis; Kenneth S Kornman; Joseph L Witztum Journal: J Am Coll Cardiol Date: 2014-02-12 Impact factor: 24.094